𝔖 Bobbio Scriptorium
✦   LIBER   ✦

XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

✍ Scribed by Maniadakis, Nikos; Fragoulakis, Vasilios; Pectasides, Dimitrios; Fountzilas, George


Book ID
126511263
Publisher
Informa plc
Year
2009
Tongue
English
Weight
178 KB
Volume
25
Category
Article
ISSN
0300-7995

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Capecitabine plus oxaliplatin (XELOX) ve
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; GΓ©rard Lledo; Thier πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF